Table 1.
Clinical and demographic characteristics.
| Characteristic | Overall, N = 11 | CR/HI, N = 6 | No Response, N = 5 | p-value1 | q-value2 |
|---|---|---|---|---|---|
| Gender, n/N (%) | >0.9 | >0.9 | |||
| Female | 2/11 (18%) | 1/6 (17%) | 1/5 (20%) | ||
| Male | 9/11 (82%) | 5/6 (83%) | 4/5 (80%) | ||
| Age, Mean+/-SD | 72.2+/-6.3 | 70.7+/-6.7 | 74.0+/-6.0 | 0.3 | >0.9 |
| Hemoglobin (g/dL), Mean+/-SD | 9.2+/-1.5 | 9.5+/-1.9 | 8.8+/-0.5 | 0.7 | >0.9 |
| Platelets (K/uL), Mean+/-SD | 137.6+/-152.7 | 134.3+/-151.3 | 141.6+/-172.1 | >0.9 | >0.9 |
| ANC (K.uL), Mean+/-SD | 4.0+/-3.9 | 4.9+/-5.1 | 3.0+/-1.9 | >0.9 | >0.9 |
| BM Blast (%), Mean+/-SD | 4.3+/-3.3 | 3.0+/-1.8 | 5.8+/-4.1 | 0.2 | >0.9 |
| Cytogenetics, n/N (%) | 0.7 | >0.9 | |||
| 8+ | 2/11 (18%) | 1/6 (17%) | 1/5 (20%) | ||
| Diploid | 8/11 (73%) | 5/6 (83%) | 3/5 (60%) | ||
| Miscellaneous | 1/11 (9.1%) | 0/6 (0%) | 1/5 (20%) | ||
| ASXL1, n/N (%) | 4/11 (36%) | 3/6 (50%) | 1/5 (20%) | 0.5 | >0.9 |
| TET2, n/N (%) | 5/11 (45%) | 3/6 (50%) | 2/5 (40%) | >0.9 | >0.9 |
| RUNX1, n/N (%) | 4/11 (36%) | 2/6 (33%) | 2/5 (40%) | >0.9 | >0.9 |
| IPSS, n/N (%) | 0.5 | >0.9 | |||
| Low | 4/11 (36%) | 3/6 (50%) | 1/5 (20%) | ||
| INT-1 | 6/11 (55%) | 3/6 (50%) | 3/5 (60%) | ||
| High | 1/11 (9.1%) | 0/6 (0%) | 1/5 (20%) | ||
| HMA, n/N (%) | >0.9 | >0.9 | |||
| Azacitidine | 8/11 (73%) | 4/6 (67%) | 4/5 (80%) | ||
| Decitabine | 3/11 (27%) | 2/6 (33%) | 1/5 (20%) |
1Statistical tests performed: Fisher’s exact test; Wilcoxon rank-sum test.
2False discovery rate correction for multiple testing.
ANC, Absolute Neutrophil Count; BM, Bone marrow; IPSS, International Prognostic Scoring System; HMA, Hypomethylating agent.